Natalie Holles

In this episode, Natalie Holles, former CEO of Third Harmonic Bio, shares her insights on the tough decisions behind dissolving the company and returning cash to shareholders. She discusses the challenges of biotech leadership amid failures, including Eli Lilly's disappointing obesity drug results and Replimmune's FDA rejection. Holles emphasizes the importance of transparency and data-driven approaches in the industry. The conversation wraps up with a humorous take on the challenges of balancing personal life with professional aspirations in biotech.